Bone Therapeutics develops therapies to prevent and treat fractures by addressing underlying problems in bone regeneration. In November, the company’s allogeneic cell therapy product, ALLOB, received Orphan Drug Designation (ODD) from the EMA and the US FDA for the treatment of the genetic bone disorder osteogenesis imperfecta. Over the next two years, we expect frequent clinical development updates from Phase II and Phase III trials to boost awareness and interest in Bone Therapeutics’ cell therapy technology and investment case.
